Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma

Bone Marrow Transplantation volume 55, pages 1172–1174 (2020)Cite this article

Subjects

Despite the expanding therapeutic armamentarium for patients with multiple myeloma, planned tandem autologous hematopoietic stem cell transplantation (AHCT) followed by reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HCT) remains an established therapy for long-term control of high-risk disease [1]. Yet, the effect of time from AHCT to allo-HCT (auto-allo-HCT time) in real-world circumstances remains unexplored. This is of interest in the era of multiple novel treatments where the efficacy of early referral to allo-HCT may be compromised by delays due to successive rounds of treatment with novel therapies.

We retrospectively analyzed 74 consecutive patients who had previously received an AHCT undergoing HLA-matched, RIC allo-HCT for myeloma from 2000 to 2017 across three centers. All institutional Review Boards approved of this study. Patient, disease and transplant characteristics are detailed in Table S1 (Supplementary Information). Median age at allo-HCT was 50 years old. Most patients (72%) had received either an immunomodulatory imide drug, proteasome inhibitor or both during induction treatment. Twenty-three percent of patients had received ≥3 lines of therapy prior to allo-HCT.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, et al. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica. 2019;104:380–91.

    Article  CAS  Google Scholar 

  2. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

    Article  Google Scholar 

  3. Montefusco V, Mussetti A, Rezzonico F, Maura F, Pennisi M, de Philippis C, et al. Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients. Bone Marrow Transpl. 2017;52:1602–8.

    Article  CAS  Google Scholar 

  4. Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transpl. 2012;18:617–26.

    Article  CAS  Google Scholar 

  5. Alessandrino EP, Porta MG, Malcovati L, Jackson CH, Pascutto C, Bacigalupo A, et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol. 2013;88:581–8.

    Article  Google Scholar 

  6. Dhakal B, D’Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, et al. Allogeneic hematopoietic cell transplantation in multiple myeloma: impact of disease risk and post allograft minimal residual disease on survival. Clin Lymphoma Myeloma Leuk. 2016;16:379–86.

    Article  Google Scholar 

  7. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005;105:4532–9.

    Article  CAS  Google Scholar 

  8. Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Lleonart JB, et al. Tandem Autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019. https://doi.org/10.1016/j.bbmt.2019.07.004. [Epub ahead of print].

Download references

Author information

Authors and Affiliations

  1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    Salvatore Fiorenza & Jordan Gauthier

  2. Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia

    David Routledge, Jenny Collins, Simon Harrison, Ashish Bajel & David Ritchie

  3. The Christie NHS Foundation Trust, Manchester, UK

    Michael Shipton & James Cavet

  4. Central Manchester NHS Foundation Trust, Manchester, UK

    Eleni Tholouli

Authors
  1. Salvatore Fiorenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Routledge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jenny Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Shipton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simon Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ashish Bajel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James Cavet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eleni Tholouli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jordan Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David Ritchie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jordan Gauthier or David Ritchie.

Ethics declarations

Conflict of interest

The authors declare that they have no relevant conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Results presented in part at 59th American Society of Hematology Annual Meeting, 2017

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fiorenza, S., Routledge, D., Collins, J. et al. Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. Bone Marrow Transplant 55, 1172–1174 (2020). https://doi.org/10.1038/s41409-019-0642-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0642-x

This article is cited by

Search

Advanced search

Quick links